Castle Biosciences (CSTL)
(Delayed Data from NSDQ)
$28.47 USD
+0.38 (1.35%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $28.47 0.00 (0.00%) 6:44 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CSTL 28.47 +0.38(1.35%)
Will CSTL be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CSTL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CSTL
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Beat Estimates
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
CSTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Castle Biosciences, Inc. (CSTL) Report Negative Earnings Next Week? What You Should Know
Zacks Market Edge Highlights: Soundhound AI, Afya, Castle Biosciences, TriMas and Immersion
5 Top Small Cap Stocks to Buy Now
Other News for CSTL
BTIG life sciences/diagnostics analyst holds an analyst/industry conference call
BTIG life sciences/diagnostics analyst holds an analyst/industry conference call
New Data at ASTRO 2024 Shows Castle Biosciences? DecisionDx?-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma
The Melanoma Research Foundation to host the Los Angeles Miles for Melanoma 5K
BTIG life sciences/diagnostics analyst holds an analyst/industry conference call